6,6,8,8,10,10-d6-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine | 1408250-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 6,6,8,8,10,10-d6-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine
• 英文别名: 5,5,7,7,9,9-Hexadeuterio-6,8-dihydrotetrazolo[1,5-a]azepine；5,5,7,7,9,9-hexadeuterio-6,8-dihydrotetrazolo[1,5-a]azepine
• CAS: 1408250-25-8
• 化学式: C₆H₁₀N₄
• 分子量: 144.125
• InChiKey: CWRVKFFCRWGWCS-CNGVIXCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4,4-Dideutero-cyclohexanon 在 sodium azide 、 四氯化硅 、 重水 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 76.0h， 生成 6,6,8,8,10,10-d6-6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine
  参考文献：
  名称：

  [EN] PENTYLENETETRAZOLE DERIVATIVES
  [FR] DÉRIVÉS DE PENTYLÈNETÉTRAZOLE

  摘要：

  提供的化合物具有以下式I的结构：( l ) 其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文所述，或其药用盐。还提供包含这些化合物的药物组合物及其使用方法，例如用于治疗老年痴呆、老年混淆、精神病、神经症，当焦虑和紧张存在时，脑动脉硬化、恶心、抑郁、疲劳、虚弱、轻微行为障碍、易怒、情绪不稳定、反社会态度、焦虑、眩晕或失禁，或其症状，或用于改善个体的认知功能，例如用于唐氏综合症患者和其他情况的个体。

  公开号：

  WO2012151343A1

文献信息

• US20140343040A1
  申请人：——

  公开号：US20140343040A1

  公开（公告）日：2014-11-20
• PENTYLENETETRAZOLE DERIVATIVES
  申请人：Balance Therapeutics, Inc.

  公开号：US20170044165A1

  公开（公告）日：2017-02-16

  Provided are compounds having formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as disclosed herein, or a pharmaceutically salt thereof. Pharmaceutical compositions comprising the compounds and methods of their use, for instance in treating senility, senile confusion, psychoses, psychoneuroses when anxiety and nervous tension were present, cerebral arteriosclerosis, nausea, depression, fatigue, debilitation, mild behavioral disorders, irritability, emotional instability, antisocial attitudes, anxiety, vertigo or incontinence, or symptom thereof, or in improving cognitive function in individuals, for instance, in individuals with Down syndrome and other conditions, are also provided.
• US9453020B2
  申请人：——

  公开号：US9453020B2

  公开（公告）日：2016-09-27
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUE
  申请人：RY PHARMA B V

  公开号：WO2016114655A1

  公开（公告）日：2016-07-21

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUES
  申请人：RY PHARMA B V

  公开号：WO2017065602A1

  公开（公告）日：2017-04-20

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Pharmaceutical compositions comprising Penicillin G and, optionally, glucocorticoid are especially useful in the present invention. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.